Das BfArM im System der europäischen Zulassungsverfahren

Prof. Dr. rer. nat. habil. Harald G. Schweim
President
Federal Institute for Drugs and Medical Devices
my home – country:
EUROPE*

*Intermediate stage 2004/7

and Turkey?
Drugs in Germany I

- big (German-speaking) market (~ 100 Mio. people)
- 60,000 approved drugs with:
  - ~ 1000 usable approvals with standardised master texts ("Muster")
  - ~ 10,000 "freshly" appr. "old products" ("Nachzulassung")
  - ~ 20,000 MRP-ready approvals (Assessment Reports)
- big market for homeophatics and herbals
- important medium-sized (and cooperative !) companies
- tradition in precision and exactness
- all global players in the market
Drugs in Germany II

- Old market workload until 31 December 2005
- Strict national regulations
- Well established court-law
- Strong (good-lobbying !) trade associations
- Need for equal treatment of approvals
- No pricing negotiations within approval procedure
Drugs in Germany III

- partly electronic application obligatory ("Einreichungsverordnung")
- many internal (partly public) databases for approved drugs
- "electronic" marketing authorisation (in progress)
- broad use of standardised master text ("Muster") approvals for known drugs
- developing new database vigilance systems
- SOPs on nearly all topics in Regulatory Affairs
- Very active scientific regulatory affairs society (DGRA)
Approval of Drugs in Germany

regulatory framework


how to gain marketing authorisation in Germany:
centralised procedure according to 2309/93/EEC
decentralised procedure according to 75/319/EEC
national procedure for new and known substances according to §§ 21, 25, 48, 49 etc. AMG
homoeopathics etc. according to §§ 34
standard approvals according to § 36 AMG
parallel import approval
old drugs ("Nachzulassung") according to § 105 AMG
Staff at BfArM (05/01/02)

965 Employees;
630 thereof female and 335 male;
695 thereof in scientific Dep./270 in administrative Dep.;
342 thereof scientists;
184 thereof female and 158 male
### BfArM – European Workload 1995 to 2002

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (Projects)</th>
<th>BfArM as (Co)Rapp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centralised Procedure (incl. Line-extension)</td>
<td>368</td>
<td>54 (ca. 16%)</td>
</tr>
<tr>
<td>Mutual Recognition</td>
<td>1877 Projects:</td>
<td>258 Projects:</td>
</tr>
<tr>
<td></td>
<td>3562 Single:</td>
<td>466 Single:</td>
</tr>
<tr>
<td></td>
<td>1362 as CMS</td>
<td></td>
</tr>
</tbody>
</table>

DE holds rank 4 of RMS countries (2002)

DE (together with SE) leading in the licensing of new substances in MR-Procedures

DE is concerned in more than 50% of all procedures and thus has the most MR licenses in Europe
Overview of Reference Member States in Decentralised Procedures
- completed procedures (Day 90) 1 January 2002 until 31 December 2002 -

As of: 31 Dec. 2002
Source: Eudratrack
Overview of Concerned Member States in Decentralised Procedures

- completed procedures (Day 90) 1 January 2002 until 31 December 2002 -

As of: 31 Dec. 2002
Source: Eudratrack
Proposals of the Commission

• Centralised or decentralised – now in balance* ?
• Mutual Recognition Committee – composition ?
• Empowerment of the Mutual Recognition Procedure
• One renewal after 5 years (?)
• "Pre-approval" pharmacovigilance ??
• "Better regulation" ?
• However, lacking definitions on:
  - NCE
  - Public health
  - Serious risk to public health

* New Commission proposal will follow a little later
Most Important Aspects of the Review for Us:

• Streamlining of Committees (number of members; process of selection; responsibility)

• Scope for centralised / decentralised procedures

• Importance of clear definitions (next slide)

• Renewal versus pharmacovigilance (following)
Need for Definition: "Serious Risk to Public Health"

• national views / definitions differ from case to case and from country to country?
• are national views always objective?
• maybe national views are "historical"?
• are national views applicable to European harmonisation / single market?
• are national views "for home use" only
  • or a "mission" to other countries?
  • Conclusion: A European definition is highly necessary.
• Already on Commission agenda, but within which time frame?
new drugs for: AIDS, oncology diabetes &
neuro-vegetative diseases (e.g. Alzheimer's)
obligatorily CENTRALISED

Generics
centralised and decentralised line-extension

FOR ONE MEMBER STATE ONLY;
bibliographic approval;
Future of national procedures?

- Abolishment of new substances in national procedures?
  and how to keep scientific knowledge??

- Abolishment of renewal procedure?
  and then what about outdated claims??

  We recommend renewals all 10 (8) years
Deficits due to Centralisation/Globalisation of Product Development + Maintenance

• Loss of national identification for:
  • academic research
  • product development
  • licensing system
  • marketing/product maintenance
  • drug safety
Deficits due to Centralisation-(ONLY) of Licensing Procedures

• Medium-sized companies' development of innovative products is inhibited by
  
in-house bundling of capacities for processing of centralised procedures
in-house costs for pursuing centralised procedures
fees for centralised procedures

It’s necessary for companies to have (as free as possible) choice of access to market
Possible Development I (Risks)

- Shift from national + decentralised procedures to centralised procedures
- Increase in monopolisation of licensing systems
- Decrease in competition
- Decrease in national identification with products
- Shifting of decisions from national to centralised anonymous EU authorities
Development II (Advantages)

- Common market
- Quality of supply with medicinal products of a consistently high European standard
- Uniform regulatory system
- Transparency
- Orientation for consumer and patient

But Pharmacovigilance always stays a national responsibility!!
Agencies Have to Define Their Position for the Future:

- Team leader and/or opinion leader?
- Centres of excellence for agencies or "full provider"?
  - according to approvals:
    - MRFG – RMS / Centralised - Rapporteur
    - according to projects / indications (e.g. antibiotics, HIV)
    - according to topics (Notes for Guidance, Points to Consider, Working Parties)
- Team player in all other cases! (The Network-System!)

.........otherwise ????
BfArM's Decisions for Contribution I

- "Full-provider"
- Scientific expertise
- Effective and efficient licensing system
- Customer orientation
- Scientific co-operation with other regulatory authorities
- Fulfilment of European and international standards
- Development of a worldwide pharmacovigilance network
National Contribution II

- Co-operation in detecting counterfeit medicinal products
- Co-operation in the field of inspections
- Development of a European strategy for consumer information
- Developments in "off-label use", "orphan drugs", and "fast-track drugs"
- We want to be part of the european network
Optimisation of European Procedures

- Excellent national and EU scientific advice
- High scientific level expertise
- Bridging of national / EU risk management
- Contribution to European pharmaceuticals market:
  Qualified "Nachzulassung" in the CC
- Quality / quality assurance
- Fast access to important drugs for all Europeans
Importance of European Procedures - Future

Regulation of access to Centralised/Mutual Recognition Procedures

Balance between Centralised and Mutual Recognition Procedures

• For 2003, only few (22+16 orphans*) new substances can be expected within the Centralised Procedure. What is the EMEA's future? (costs ?, fees ?, 240 employees must be paid !)

  • Therapeutic advisory groups as "European FDA starting point"??
  • Variations Type IA (and some Type IB) to be handled by EMEA ??

"An open door may tempt a saint"

* source: EMEA/MB/057/02/en/Final
"Premium products" (innovative) centralised procedure focussed on AIDS, cancer, neuro-deg. diseases and therapeutic innovations, technologies new therapeutic principles

"Bread-and-butter products" mutual recogn./national known* biotechnological products (e.g. insulins) known chemical substances and combinations thereof other new substances and generics "former*" innovative classes of products "important" herbals

* Only "Diamonds are forever!"
Fulfilment of the EMEA Tasks ("Secretariate" !)

++ Co-ordination, project management
(+) Platform for decision making
(still possible after Court of Justice on OCs-3, anorectics, Capoten?)
+- Transparency, websites etc.
- Archiving, documentation, data-bases (pending)
-- EUDRA xxx products (deficitary)
(+) Success monitoring, cost-performance accounting, quality assurance
- Personnel required per application (too much administration?)

Fulfilment of the Agency's Tasks ("Scientific Body" !)

+ Scientific evaluation (professional work = service for EMEA)
+ Experts in a stand-by mode
+ Implementation of the European idea in MR-Procedures
(+) Translation of recognition into national licenses
-- ! Avoidance of double offers / double work
WHAT? WHERE?

- Expertise, co-coordination -- at home
- Co-operation -- on site (London, Brussels)
  - HoA, MRFG, MB, Ph-Com
  - CPMP, COMP, SciARG, ORGAM, WP's, ad hoc groups
- “Topic Leader” of the BfArM at ICH:
  - eCTD; Quality; BIOTEC; SAFTEY; VIGILANCE
- Delegation
  - to Commission
  - to EMEA
Role and Tasks of the Agencies in the Future

to be clarified:

• How to survive ?? (Especially small ones)

• Centre of excellence (EU and CC) ?? or "full provider" ??
BfArM’s Proposed Solution

• Cooperation on a network-basis

• Promotion of research and development via scientific expertise

• The larger ones as "full providers"

• The smaller ones as centres of excellence

• Cooperation within the procedures
In Wirklichkeit würden die Ferkel ihrer Freundin Sai Mai nie etwas antun. Die Tigerin wurde nämlich selbst vier Monate lang von einem Schwein gesäugt, als sie noch ein Baby war.

Raubüberfall

Die Chance hatte dieser bedauernswerte bengalische Tiger, als er am Mittwoch von einer Bande blutrünstiger Banditen-Ferkel überwältigt wurde.
Use of Experts in BfArM

- BfArM as a large competent authority has many internal experts in the fields of:
  - Regulatory affairs
  - Pharmaceutical quality
  - Non-clinical issues
  - Clinical issues
  - Pharmacovigilance

- But wants (and practices) use of external experts from Candidate Countries
Experts in BfArM

• National procedures
  (Internal and external experts)
• Mutual recognition procedures
  (Internal experts*, external experts only in exceptional cases)
• Centralised procedures
  (Internal experts only*)

(* with the exception of CC colleagues)